Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

Withdrawn before enrolling · Phase 4

Conditions studied: Clostridium Difficile Infection

In brief

Clostridium difficle infection is the leading cause of hospital acquired infection and infectious diarrhea in hospitalized patients. Eradication treatment for this infection is the challenging tasks for clinicians due to treatment resistance developed from new hypervirulent strains. The recurrence rate of this infection is around 20% and there is high likelihood(60-70%) of another episode after index recurrence. Given constant challenge new treatment options are under study. Aim of the study is to evaluate if use of bismuth subsalicylate (BSS) can decrease the length of stay in patients admitted with Clostridium difficile infection. Secondarily investigators will also see if there is any impact of BSS in decrease the recurrence.

Key facts

Study ID

NCT03592082

Run by

Bassett Healthcare

People needed

0

Starts

2018-03-01

Expected to finish

2018-07-01

Last updated by the study team

2018-07-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 or older
• Hospitalized patient with documented positive stool test for CDiff
• Able and willing to provide informed consent

You may not qualify if…

• Pregnancy
• Breastfeeding
• Known allergy to BSS or other salicylates, including aspirin
• History of bleeding disorder
• History of gastrointestinal bleed,
• History of gastrointestinal ulcer
• Chronic use of anticoagulants
• Chronic NSAID use

Where it is running

• Bassett Healthcare Network — Cooperstown, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.